Showing results (391-400 of 413) with videos related to
Sort By:
Pageof 42
Breast Cancer Research and Treatment|May 4, 2015
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2017
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy TrialsPoornima Saha, Meredith M Regan, Olivia Pagani, et al.The Lancet. Oncology|March 16, 2013
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trialViviana Galimberti, Bernard F Cole, Stefano Zurrida, et al.BMC Genomics|January 13, 2023
A draft Diabrotica virgifera virgifera genome: insights into control and host plant adaption by a major maize pest insectBrad S Coates, Kimberly K O Walden, Dimpal Lata, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function TrialKarin Ribi, Weixiu Luo, Jürg Bernhard, et al.The New England Journal of Medicine|March 12, 2004
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerR Charles Coombes, Emma Hall, Lorna J Gibson, et al.British Journal of Cancer|January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.British Journal of Cancer|April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT TrialsOlivia Pagani, Barbara A Walley, Gini F Fleming, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 13, 2021
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen SubstudyG Jerusalem, S Farah, A Courtois, et al.Pageof 42